The 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy

The Body Covers:

The 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy

Toronto, Canada

September 13-15, 2000

Conference Summaries
Related Articles and Reports

Pablo Tebas, M.D.
Recent years have seen countless reports of metabolic abnormalities in HIV-infected people treated with highly active antiretroviral therapy (HAART). Manifestations of these metabolic abnormalities include facial wasting, breast enlargement, and "buffalo hump," among other complications. Little is understood about this syndrome, called lipodystrophy, and that's why a conference was initiated in 1999 -- the First International Workshop on Adverse Drug Reactions and Lipodystrophy -- to address these problems. This year's conference will be held in Toronto and The Body is pleased to have Dr. Pablo Tebas covering it. Dr. Tebas is an Assistant Professor of Medicine at Washington University School of Medicine, medical director of the oupatient clinic of the Infectious Diseases Division, and investigator in the AIDS Clinical Trial Unit at Washington University.

Funding for this conference coverage at the Body is provided, in part, through unrestricted educational grants by Bio-Technology Group Corp. and Glaxo Wellcome.

The Body's Conference Summaries

Day Two
Thursday,
September 14 Day Three
Friday,
September 15

Introduction
Physiology of Lipoatrophy
Lessons from Lipodystrophic Mice: A Vicious Cycle
Inborn and Induced Defects of the Mitochondrial Respiratory Chain
Decrease of Mitochondrial DNA Content in Adipose Tissue of HIV-1 Infected Patients Treated with NRTIs
Subcutaneous Adipose-Tissue Mitochondrial DNA Analysis from Individuals with HAART-Associated Lipodystrophy
Metabolic Effects of Indinavir in Healthy HIV Seronegative Subjects
Assessment of Growth Hormone Physiology in the HIV Lipodystrophy Syndrome
The Effects of Recombinant Human Growth Hormone (GH) on Glucose Metabolism and Body Composition in HIV-Positive Subjects with Fat Accumulation (FA) Syndromes

Genes, Diet, and Atherogenic Dyslipidemia
HIV Protease Inhibitors Increase Secretion of Apolipoprotein B-lipoproteins from Hepatoma Cells by Preventing Proteasomal Degradation
Differences in Postprandial Lipid Metabolism in Patients with PI-Associated and NRTI-Associated Lipodystrophy
Increased tPA Antigen Levels in the HIV Lipodystrophy Syndrome are Reduced in Response to Metformin
Role of Endothelial Dysfunction in Atherosclerosis
Metabolic Complications: The Need for Perspective
Use of HIV Protease Inhibitors is Associated with Endothelial Dysfunction
IMT as Cardiovascular Risk Marker in HIV+ Patients Treated and Untreated with Protease Inhibitors
Lessons Learned from Switching Antivirals
Lipodystrophy and Metabolic Abnormalities in a Cross-Sectional Study of Participants in Randomized-Controlled Studies of Combination Antiretroviral Therapy (ARV)
Serum and Urine Markers of Bone Mineral Metabolism in HIV-Infected Patients Taking Protease Inhibitor-Containing Potent Antiretroviral Therapy
Longitudinal Analysis of Bone Mineral Density (BMD) in HIV-infected Patients Treated with HAART: Changes in BMD Correlate with Change in Subcutaneous Fat; with an Additional Independent Effect of Indinavir Therapy to Increase BMD
Osteopenia in HIV-Infected Men: Association with Lactic Acidemia and Lower Weight Pre-Antiretroviral Therapy
Case-control Study of Avascular Necrosis (AVN) in HIV-Infected Patients
Metabolic and Clinical Evaluation of Lipodystrophy 48 Weeks After Switching from Two Nucleoside Reverse Transcriptase Inhibitors/Protease Inhibitor to Two Nucleoside Reverse Transcriptase Inhibitors/Abacavir (French Substudy, CNA 30017)
Switching from Protease Inhibitor to Nevirapine-Based Potent Antiretroviral Therapy Increases Lean Body Mass
HIV-Protease Inhibitor Switch to Nevirapine Improves Insulin Tolerance but Does not Correct Adipose Tissue Maldistribution
A Randomized, Multicentre Study of Protease Inhibitor Substitution in Aviraemic Patients with Lipodystrophy (LD): 48-Week Data
Fat Redistribution Syndrome/Lipodystrophy and Anabolic Agents: Results of a Large Multicenter U.S. Study

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.